Steven A Rosenberg

This inventor holds 148 USPTO granted patents and 53 published patent applications, plus 21 CIPO patents and 48 EPO patents, primarily in T Cell Therapy (CPC class C07K14-7051). Top assignees: The United States of America, as Represented by the Secretary, Department of Health and Human Services, The United States of America as Represented by the Department of Health, Intima Bioscience, Inc.. Active years: 1987-2026.

USPTO Granted Patents = 148 (Patent Applications = 53)

% Patents Active = 83.8

CIPO Patents = 21 (Patent Applications = 14)

EPO Patents = 48 (Patent Applications = 79)

Average Co-Inventor Count = 2.7

ph-index = 26

Forward Citations = 3,389(Granted Patents)

Forward Citations (Not Self Cited) = 3,032(Dec 10, 2025)

Inventors with similar research interests:

🔬 See more inventors

Location History:

South Plainfield, NJ (US) (1995 - 2012)
Bethesda, MD (US) (1987 - 2023)
Potomac, MD (US) (1998 - 2024)

Company Filing History:

126 out of 3,690

The United States of America, as Represented by the Secretary, Department of Health and Human Services

patents

12 out of 1,217

The United States of America as Represented by the Department of Health

patents

11 out of 15

Intima Bioscience, Inc.

patents

4. 11 out of 2,367

Regents of the University of Minnesota

The United States of America as Represented by the Secretary of

The Government of the United States of America, as Represented by the

patents

9. 1 out of 13

The United States of America as Represented by the Secretary, Department

patents

10. 1 out of 1

The United States of America, as Represented by the Secretary, Department of Health and Human Serv

patent

11. 1 out of 15

Therion Biologics Corporation

patents

12. 1 out of 33

Wilson Wolf Manufacturing Corporation

patents

13. 1 out of 1,168

Yeda Research and Develpment & Co. Ltd

patents

14. 4 out of 834,411

Other

patents

where one patent can have more than one assignee

Years Active: 1987-2026

Loading Chart...

Areas of Expertise:

T Cell Receptors

Cancer-Specific Mutations

Patient Conditioning

HLA Class II

KRAS-G12D

MAGE-A3

Anti-Human Papillomavirus

Tumor Infiltrating Lymphocytes

Neoantigen-Specific

Dendritic Cells

Therapeutic Methods

148 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12721890 - T CELL RECEPTORS RECOGNIZING R273C OR Y220C MUTATIONS IN P53 (2026-09-01),

2. 12702706 - Methods of preparing anti-human papillomavirus antigen T cells (2026-08-11),

3. 12673981 - T CELL RECEPTORS RECOGNIZING HLA-CW8 RESTRICTED MUTATED KRAS (2026-07-07),

4. 12655195 - HLA CLASS II-RESTRICTED DQ T CELL RECEPTORS AGAINST RAS WITH G13D MUTATION (2026-06-16),

5. 12655194 - HLA CLASS II-RESTRICTED DRB T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION (2026-06-16),

6. 12655193 - HLA CLASS II-RESTRICTED DRB T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION (2026-06-16),

7. 12630802 - METHODS OF ISOLATING T CELLS AND T CELL RECEPTORS HAVING ANTIGENIC SPECIFICITY FOR A CANCER-SPECIFIC MUTATION FROM PERIPHERAL BLOOD (2026-05-19),

8. 12534508 - ANTI-HUMAN PAPILLOMAVIRUS 16 E7 T CELL RECEPTORS (2026-01-27),

9. 12479902 - T CELL RECEPTORS RECOGNIZING R175H OR Y220C MUTATION IN P53 (2025-11-25),

10. 12458654 - Methods of conditioning patients for T cell therapy (2025-11-04),

11. 12448428 - HLA class II-restricted t cell receptors against RAS with G12R mutation (2025-10-21),

12. 12441778 - T cell receptors recognizing HLA-A1-restricted MAGE-A3 (2025-10-14),

13. 12404317 - T cell receptors recognizing MHC class II-restricted MAGE-A3 (2025-09-02),

14. 12391742 - Anti-KRAS-G12D T cell receptors (2025-08-19),

15. 12304940 - HLA class II-restricted t cell receptors against mutated RAS (2025-05-20),

Title: The Innovative Journey of Steven A. Rosenberg

Introduction: Steven A. Rosenberg, a distinguished inventor based in Potomac, MD (US), has made significant contributions to the field of innovation through his groundbreaking work in various patents.

Latest Patents: Steven A. Rosenberg holds several patents in the areas of medical devices and biotechnology, focusing on advancements in cancer treatment and personalized medicine.

Career Highlights: With a career spanning over three decades, Steven A. Rosenberg has established himself as a leading figure in the world of inventors. His innovative solutions have revolutionized the way we approach healthcare and have led to improved patient outcomes.

Collaborations: Throughout his career, Steven A. Rosenberg has collaborated with top research institutions, universities, and medical professionals to further his inventions and bring them to market. His collaborative spirit has been instrumental in the success of his patented technologies.

Conclusion: Steven A. Rosenberg's dedication to innovation and his relentless pursuit of excellence have solidified his reputation as a visionary inventor. His work continues to inspire future generations of inventors to push the boundaries of what is possible in the world of patents and inventions.